Herpes Zoster (Shingles)-Pipeline Review, H2 2015

Herpes Zoster (Shingles)-Pipeline Review, H2 2015


  • Products Id :- GMDHC7271IDB
  • |
  • Pages: 65
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Herpes Zoster (Shingles)-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Herpes Zoster (Shingles)-Pipeline Review, H2 2015', provides an overview of the Herpes Zoster (Shingles)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Herpes Zoster (Shingles) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Herpes Zoster (Shingles) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Herpes Zoster (Shingles) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Herpes Zoster (Shingles) Overview 7

Therapeutics Development 8

Pipeline Products for Herpes Zoster (Shingles)-Overview 8

Pipeline Products for Herpes Zoster (Shingles)-Comparative Analysis 9

Herpes Zoster (Shingles)-Therapeutics under Development by Companies 10

Herpes Zoster (Shingles)-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Herpes Zoster (Shingles)-Products under Development by Companies 15

Herpes Zoster (Shingles)-Companies Involved in Therapeutics Development 16

Astellas Pharma Inc. 16

Beijing Minhai Biotechnology Co., Ltd 17

Epiphany Biosciences, Inc. 18

Foamix Pharmaceuticals Ltd. 19

GlaxoSmithKline Plc 20

Merck & Co., Inc. 21

NAL Pharmaceuticals Ltd. 22

Spider Biotech 23

TSRL, Inc. 24

Herpes Zoster (Shingles)-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

acyclovir-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

amenamevir-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

FV-100-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

GSK-1437173A-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

herpes zoster vaccine-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

NAL-3221-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

NAL-3223-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

SB-105A10-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

TSR-087-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

V-212-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

valomaciclovir stearate-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Herpes Zoster (Shingles)-Recent Pipeline Updates 50

Herpes Zoster (Shingles)-Dormant Projects 55

Herpes Zoster (Shingles)-Discontinued Products 56

Herpes Zoster (Shingles)-Product Development Milestones 57

Featured News & Press Releases 57

Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain 57

Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial 57

Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied 58

Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN 58

Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint 59

Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant 59

Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles 60

Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles 60

Apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster and Post-herpetic Neuralgia in Older US Population, Cohort Study Finds 61

Jul 18, 2012: Agenus Announces Initiation of Phase III Clinical Trial of GSK's Herpes Zoster Vaccine Candidate in Immunocompromised Patients 62

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65

List of Tables

Number of Products under Development for Herpes Zoster (Shingles), H2 2015 8

Number of Products under Development for Herpes Zoster (Shingles)-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Late Stage Development, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Comparative Analysis by Unknown Stage Development, H2 2015 14

Products under Development by Companies, H2 2015 15

Herpes Zoster (Shingles)-Pipeline by Astellas Pharma Inc., H2 2015 16

Herpes Zoster (Shingles)-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 17

Herpes Zoster (Shingles)-Pipeline by Epiphany Biosciences, Inc., H2 2015 18

Herpes Zoster (Shingles)-Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 19

Herpes Zoster (Shingles)-Pipeline by GlaxoSmithKline Plc, H2 2015 20

Herpes Zoster (Shingles)-Pipeline by Merck & Co., Inc., H2 2015 21

Herpes Zoster (Shingles)-Pipeline by NAL Pharmaceuticals Ltd., H2 2015 22

Herpes Zoster (Shingles)-Pipeline by Spider Biotech, H2 2015 23

Herpes Zoster (Shingles)-Pipeline by TSRL, Inc., H2 2015 24

Assessment by Monotherapy Products, H2 2015 25

Number of Products by Stage and Target, H2 2015 27

Number of Products by Stage and Mechanism of Action, H2 2015 29

Number of Products by Stage and Route of Administration, H2 2015 31

Number of Products by Stage and Molecule Type, H2 2015 33

Herpes Zoster (Shingles) Therapeutics-Recent Pipeline Updates, H2 2015 50

Herpes Zoster (Shingles)-Dormant Projects, H2 2015 55

Herpes Zoster (Shingles)-Discontinued Products, H2 2015 56

List of Figures

Number of Products under Development for Herpes Zoster (Shingles), H2 2015 8

Number of Products under Development for Herpes Zoster (Shingles)-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Early Stage Products, H2 2015 13

Assessment by Monotherapy Products, H2 2015 25

Number of Products by Top 10 Targets, H2 2015 26

Number of Products by Stage and Top 10 Targets, H2 2015 26

Number of Products by Top 10 Mechanism of Actions, H2 2015 28

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 28

Number of Products by Top 10 Routes of Administration, H2 2015 30

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 30

Number of Products by Top 10 Molecule Types, H2 2015 32

Number of Products by Stage and Top 10 Molecule Types, H2 2015 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Astellas Pharma Inc.

Beijing Minhai Biotechnology Co., Ltd

Epiphany Biosciences, Inc.

Foamix Pharmaceuticals Ltd.

GlaxoSmithKline Plc

Merck & Co., Inc.

NAL Pharmaceuticals Ltd.

Spider Biotech

TSRL, Inc.

Herpes Zoster (Shingles) Therapeutic Products under Development, Key Players in Herpes Zoster (Shingles) Therapeutics, Herpes Zoster (Shingles) Pipeline Overview, Herpes Zoster (Shingles) Pipeline, Herpes Zoster (Shingles) Pipeline Assessment

select a license

Single User License
USD 2000 INR 128520
Site License
USD 4000 INR 257040
Corporate User License
USD 6000 INR 385560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com